Over 7 billion yuan of peptic ulcer retail market, 39% of which are gastric proton pump inhibitors

Peptic ulcer (PU) refers to the inflammatory reaction and necrotic lesion of mucosa under the action of various pathogenic factors The lesion reaches to the muscularis of mucosa and often occurs in the gastrointestinal mucosa related to gastric acid secretion More than 95% of them are gastric ulcer and duodenal ulcer Peptic ulcer is a kind of common chronic disease, which has the characteristics of long-term recurrent attack It is seasonal recurrent attack It is most likely to occur in spring and autumn and winter This disease can be seen at any age, mostly 20-50 years old, more men than women, about 10% of the people in their lifetime have suffered from peptic ulcer With the acceleration of people's living rhythm and the change of living habits, the number of patients with peptic ulcer caused by improper eating habits is on the rise The market of peptic ulcer drugs is expanding year by year In 2016, the market scale of anti peptic ulcer drugs in retail pharmacies reached 7.43 billion yuan, an increase of 2.1% year on year It is expected to exceed 8 billion yuan in 2017 Growth of peptic ulcer drug market in retail pharmacies in 2013-2017e in 2016, prescription drugs and over-the-counter drugs of anti peptic ulcer drugs accounted for half of the total market From the perspective of share in recent years, due to the influence of prescription outflow and pharmaceutical industry division policies, prescription drugs of anti peptic ulcer in retail pharmacies expanded steadily, with market share increasing year by year In 2013-2017e, the proportion of Rx and OTC of peptic ulcer drugs in retail pharmacies was mainly composed of chemical drugs, accounting for 70.5% of the market share, which was expanding year by year; while the market share of Chinese patent medicine decreased, accounting for 29.4% Peptic ulcer has the characteristics of periodicity and recurrence At the early stage of the disease, patients prefer to buy medicine in the drugstore The anti peptic ulcer drugs in the retail drugstore are mainly chemical drugs and proprietary Chinese medicine In 2013-2017e, the proportion of Chinese patent medicine and chemical medicine of peptic ulcer medicine in retail drugstores included gastric proton pump inhibitor, antacid, gastric mucosal protective medicine, H2 receptor blocker, etc.; Chinese patent medicine was Qi regulating agent, Wenli agent, etc In terms of market share of sub categories of anti peptic ulcer drugs in retail pharmacies in 2016, the proportion of gastric proton pump inhibitors is 39%, which is the largest class of drugs for peptic ulcer treatment in the market at present Qi regulating agent is a kind of traditional Chinese medicine which is widely used in the treatment of peptic ulcer Its best-selling varieties include Weikangling, Sanjiu Weitai, Weisu, etc Market share of main categories of anti peptic ulcer drugs specific varieties of gastric proton pump inhibitors include omeprazole, rabeprazole, esomeprazole, pantoprazole and lansoprazole, with annual sales of over 100 million yuan Omeprazole, lansoprazole and pantoprazole belong to the first generation of PPIs, rabeprazole and esomeprazole belong to the second generation Compared with the first generation, omeprazole has faster effect, stronger acid inhibition and more lasting effect In recent years, the share of various varieties in retail pharmacies has remained relatively stable In 2013-2017e, the proportion of gastric proton pump inhibitors in retail pharmacies changed There are many varieties of drugs for peptic ulcer treatment, with the market share of top 10 varieties totaling 64%, and the variety concentration is high Among the top 10 varieties, there are 5 gastric proton pump inhibitors, the first one is omeprazole, with a market share of 20.8% in 2016 Omeprazole is the original product of AstraZeneca In 2016, the drug use scale of retail pharmacies exceeded 1.5 billion yuan About 100 domestic manufacturers participated in the division of this market The competition of this product is extremely fierce In addition to AstraZeneca, the annual sales of omeprazole produced by stone Pharmaceutical Group and Dino Pharmaceutical Co., Ltd exceed 100 million yuan Weikangling is the best Chinese patent medicine variety in the retail drugstore market, with a market share of 5.8% in 2016 It mainly functions to soften the liver and stomach, disperse stasis, relieve pain in a slow and urgent way From 2014 to 2016, there were a large number of manufacturers of top 10 varieties (100 million yuan) of peptic ulcer drugs in retail pharmacies Local enterprises dominate the market of anti peptic ulcer drugs in retail pharmacies, accounting for 78% of the market share in 2016 The market of anti peptic ulcer drugs is relatively mature, the number of domestic generic manufacturers is large, and the competition is fierce In addition to Sanjiu Weitai and Weisu, the top 10 varieties have a number of generic pharmaceutical enterprises participating in the competition Some original research enterprises, such as rabeprazole and pantoprazole, have a much smaller market share in retail pharmacies than local generic pharmaceutical enterprises In 2013-2017e, the share of domestic and foreign manufacturers of peptic ulcer drugs in retail pharmacies accounted for 48.1% of the top 10 manufacturers, compared with 49.8% in 2014, and the market concentration decreased Foreign funded enterprises occupy the top two seats, AstraZeneca and Bayer respectively, and the other eight are domestic enterprises, including revisionary, China Resources, sunflower, petrochemicals, etc., with domestic enterprises taking a significant advantage AstraZeneca's market share in the field of peptic ulcer is far ahead of other manufacturers, with a market share of 10.7% in 2016 Its varieties are omeprazole and esomeprazole, both of which are the original heavy-duty varieties Bayer's market share in 2016 accounted for 6.0%, ranking among the top three in the field of peptic ulcer medicine, relying on the variety of aluminum and magnesium carbonate, with an annual sales volume of more than 100 million yuan in retail pharmacies The revised pharmaceutical industry ranks the second in the field of peptic ulcer, with a market share of 6.2%, and the main product is vitamin U belladonna aluminum (iodomethyl methionine) In addition, China Resources's Sanjiu Weitai, sunflower's Weikangling and Yangzi River's Weisu are the main contribution varieties in the field of peptic ulcer, and they are good Chinese patent medicine brands in retail pharmacies Top 10 manufacturers of peptic ulcer drugs in retail pharmacies in 2014-2016 (100 million yuan)